EUVIMEDEUVIMED entdecken
Crossref

Utility of GLI1 RNA Chromogenic in Situ Hybridization in Distinguishing Basal Cell Carcinoma From Histopathologic Mimics

Tyler D Menge, Joseph S Durgin, Steven M Hrycaj, Ashley A Brent, Rajiv M Patel, Paul W Harms, Douglas R Fullen, May P Chan, Scott C Bresler

Modern Pathology · 2023

DOI: 10.1016/j.modpat.2023.100265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023. Verfasst von Tyler D Menge und 8 weiteren Autor:innen. Beteiligte Einrichtung: CTA Pathology, Ann Arbor, Michigan; Department of Dermatology, VA Ann Arbor Healthcare System, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Skin Neoplasms, In Situ Hybridization, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Department of Pathology, Northwestern University, University of Michigan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Basal cell carcinoma (BCC) is the most common human malignancy and is a leading cause of nonmelanoma skin cancer-related morbidity. BCC has several histologic mimics which may have treatment and prognostic implications. Furthermore, BCC may show alternative differentiation toward a variety of cutaneous structures. The vast majority of BCCs harbor mutations in the hedgehog signaling pathway, resulting in increased expression of the GLI family of transcription factors. GLI1 immunohistochemistry has been shown to discriminate between several tumor types but demonstrates high background signal and lack of specificity. In this study, we evaluated the utility of GLI1 RNA chromogenic in situ hybridization (CISH) as a novel method of distinguishing between BCC and other epithelial neoplasms. Expression of GLI1 by RNA CISH was retrospectively evaluated in a total of 220 cases, including 60 BCCs, 37 squamous cell carcinomas (SCCs) including conventional, basaloid, and human papillomavirus infection (HPV)-associated tumors, 16 sebaceous neoplasms, 10 Merkel cell carcinomas, 58 benign follicular tumors, and 39 ductal tumors. The threshold for positivity was determined to be greater than or equal to 3 GLI1 signals in at least 50% of tumor cells. Positive GLI1 expression was identified in 57/60 BCCs, including metastatic BCC, collision lesions with SCC, and BCCs with squamous, ductal, or clear cell differentiation or with other unusual features compared to 1/37 SCCs, 0/11 sebaceous carcinomas, 0/5 sebaceomas, 1/10 Merkel cell carcinomas, 0/39 ductal tumors, and 28/58 follicular tumors. With careful evaluation, GLI1 RNA CISH is highly sensitive (95%) and specific (98%) in distinguishing between BCC and nonfollicular epithelial neoplasms. However, GLI1 CISH is not specific for distinguishing BCC from most benign follicular tumors. Overall, detection of GLI1 RNA by CISH may be a useful tool for precise classification of histologically challenging basaloid tumors, particularly in the setting of small biopsy specimens, metaplastic differentiation, or metastatic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell CarcinomaSkin NeoplasmsIn Situ HybridizationBiomarkers, TumorTranscription FactorsCarcinoma, Squamous CellHumansZinc Finger Protein GLI1Diagnosis, DifferentialRetrospective StudiesFemaleMaleAgedMiddle AgedAged, 80 and overAdultImmunohistochemistryPredictive Value of Tests

Stichwörter der Autor:innen

basal cell carcinomahedgehogsebaceous carcinomasquamous cell carcinoma

Substanzen

Zinc Finger Protein GLI1GLI1 protein, humanBiomarkers, TumorTranscription Factors

Autor:innen und Institutionen

  • CTA Pathology, Ann Arbor, Michigan; Department of Dermatology, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.
  • Department of Dermatology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.
  • Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.
  • Department of Dermatology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan; Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan; Cutaneous Pathology, WCP Laboratories I…
  • Department of Dermatology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan; Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.
  • Department of Dermatology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan; Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: sbresler@med.umich.…

Förderung

  • Department of Pathology, Northwestern University
  • University of Michigan

Zitieren

APA

Menge, T. D., Durgin, J. S., Hrycaj, S. M., Brent, A. A., Patel, R. M., Harms, P. W., Fullen, D. R., Chan, M. P., & Bresler, S. C. (2023). Utility of GLI1 RNA Chromogenic in Situ Hybridization in Distinguishing Basal Cell Carcinoma From Histopathologic Mimics. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100265

Vancouver

Menge TD, Durgin JS, Hrycaj SM, Brent AA, Patel RM, Harms PW, et al. Utility of GLI1 RNA Chromogenic in Situ Hybridization in Distinguishing Basal Cell Carcinoma From Histopathologic Mimics. Modern Pathology. 2023. doi:10.1016/j.modpat.2023.100265

BibTeX
@article{Menge2023,
  author = {Menge, Tyler D and Durgin, Joseph S and Hrycaj, Steven M and Brent, Ashley A and Patel, Rajiv M and Harms, Paul W and Fullen, Douglas R and Chan, May P and Bresler, Scott C},
  title = {Utility of GLI1 RNA Chromogenic in Situ Hybridization in Distinguishing Basal Cell Carcinoma From Histopathologic Mimics},
  journal = {Modern Pathology},
  year = {2023},
  doi = {10.1016/j.modpat.2023.100265}
}
Kostenlos starten →